secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001372514-26-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals reports FY2025 net loss of $10.8M; two Phase 2 trials underway
--------------------------------------------------------------------------------

- Net loss of $10.8M for 2025 vs net income of $3.6M in 2024 due to $16M upfront payment from Théa in prior year.
- Cash, equivalents and short-term investments of $17.1M as of Dec 31, 2025; expects runway into late 2027.
- KIO-301 Phase 2 ABACUS-2 trial for retinitis pigmentosa advancing; initial data readout expected Q3 2027.
- KIO-104 Phase 2 KLARITY trial for macular edema dosing; non-cash impairment charge in Q4.
- Executed option agreement with Senju for KIO-301 in Asia with potential value up to $110M plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000025/0001372514-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000025/kprx-20260325.htm
  HTML page:      https://secwatch.observer/filing/0001372514-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer